Axsome reported strong fourth-quarter sales Tuesday, but AXSM stock tumbled on a setback for the company’s Alzheimer’s agitation treatment.
The post Axsome Tumbles On An Unexpected Setback For Its Alzheimer’s Drug appeared first on Investor’s Business Daily.